QR678 Neo®, a next-generation patented biomimetic peptide formulation developed in India, has achieved a major milestone in hair restoration. A global clinical trial, published in the Journal of Cosmetic and Laser Therapy, validated its efficacy in hair transplant surgery. The study, involving 112 men with advanced hair loss, demonstrated that QR678 Neo® delivers 43% better graft survival, fuller regrowth, and visibly improved hair quality compared to conventional transplant methods.
An Indian Innovation with Global Recognition
Developed and clinically tested in India, QR678 Neo® is now patented in the United States as well. With androgenetic alopecia affecting 85% of men by age 50 and 50% of women by age 60, the demand for effective transplant outcomes continues to grow. Unlike traditional storage mediums such as cold saline or PRP, which provide only temporary preservation without biological activity, QR678 Neo® plays an active role throughout the transplant journey.
Active Support Before, During, and After Surgery
Administered in three stages—before, during, and after surgery—QR678 Neo® nourishes the scalp, protects extracted grafts, and accelerates post-operative recovery. By mimicking natural growth factors with its proprietary blend of biomimetic peptides, the therapy creates a regenerative environment that enhances follicle survival, boosts healing, and improves both density and quality of regrown hair.
Solving the Challenge of Poor Graft Survival
Even with advanced Follicular Unit Extraction (FUE) techniques, poor graft survival remains a major concern. This often leads to patchy regrowth, inconsistent outcomes, and repeat procedures. QR678 Neo® addresses this challenge directly by rejuvenating the donor area, protecting extracted grafts, and enhancing transplanted hair regrowth at every stage. The result is consistent, superior outcomes and higher patient satisfaction.
Global Expert Validation
As per the press release, the international trial was led by experts from India, the USA, and Malaysia, including Dr. Michael Gold, Dr. Vinay Chouksey, Dr. Ungku Mohd Shahrin, and Dr. Mahesh Gosavi. Their findings underscore QR678 Neo®’s transformative role in hair restoration.
- Dr. Michael H. Gold (USA) highlighted the consistent results across patients and settings, noting that biologically active therapies are redefining transplant success.
- Dr. Ungku Shahrin (Malaysia) emphasized that the innovation raises global standards for hair restoration by delivering reproducible and scalable results.
- Dr. Mahesh Gosavi (India) pointed out faster recovery, reduced repeat surgeries, and greater patient confidence as key advantages.
- Dr. Vinay Chouksey (India) noted that the therapy aligns with the growing demand for minimally invasive regenerative solutions in a market valued at over $4 billion.
A Clinically Validated, Patented Solution
QR678 Neo® is a non-blood-based regenerative formulation that enhances cellular viability, tissue healing, and vascularization at graft sites. Across clinical settings, it consistently outperformed cold saline in follicle survival, hair density, regrowth, and patient satisfaction. With 14+ clinical trials worldwide validating its efficacy, QR678 Neo® has established itself as a safe, minimally invasive, and scalable innovation.
India’s Leadership in Global Hair Restoration
Arriving at a pivotal moment for the $4 billion hair restoration market, QR678 Neo® reflects India’s leadership in biotech-driven healthcare. By delivering measurable patient benefits and setting new standards in graft survival and regrowth, this Indian-led innovation stands as a transformative breakthrough in the global field of regenerative therapies.